LPS-protected animals showed higher frequency and number of CD4+Foxp3+ T cells in the spleen and pLN, when compared to healthy controls (Figs. 5A and S4). Expression of CD25 by Foxp3+ Treg is believed to identify active Treg presumably exposed to IL-2 produced by effector cells. LPS-protected mice showed enrichment in the

proportion of Foxp3+ cells within the CD4+CD25+ compartment in pLN (Fig. 5B). In the spleen, the frequencies of Foxp3+ cells were increased in the CD4+CD25− (Fig. 5C) and not in the CD4+CD25+ cell subset (Fig. 5B), although the levels of Foxp3 expression within the latter were somewhat enhanced (Fig. S5). Together, these results suggest that LPS treatment promoted Treg activation. Analysis of thymocytes showed no significant difference in the frequency and number of CD4+Foxp3+ this website cells in LPS-treated as Angiogenesis inhibitor compared to healthy controls (Fig. S6), indicating that the LPS effects on Treg are restricted to the periphery. We conclude that LPS treatment promoted the activation and accumulation of CD4+ cells with a regulatory phenotype. The findings above suggested that enhanced Treg activity prevented effector cell diabetogenic potential activity in LPS-protected NOD mice.

According to this scenario, effector cells from LPS-treated animals would cause severe diabetes if unleashed from Treg control. To directly test this hypothesis we performed adoptive transfer of splenocytes isolated from either diabetic, healthy controls or LPS-treated mice, into alymphoid NOD/SCID animals. We first analysed female recipient mice that had received 5 × 106 total splenocytes obtained from 6- to 7-month-old NOD females (Fig. 6A). As expected, all female recipients of cells isolated from sick donors developed diabetes 7 weeks post-adoptive transfer. Intriguingly, disease onset was not significantly delayed in mice ZD1839 manufacturer that had received cells from healthy donors and diabetes incidence reached 100% by 12 weeks post-transfer.

Similar results were obtained when NOD/SCID male received splenocytes prepared from 7-month-old diabetic or disease-free NOD males (Fig. S7A). These results confirmed that diabetes is transferable upon injection of total splenocytes while spontaneous resistance to diabetes seemed not. In contrast, mice recipient of cells isolated from LPS-treated donors developed diabetes more than 5 weeks later than any of the control groups. Notably, at 12 weeks post-transfer, when all control mice were readily sick, only two of 14 (14.3%) female recipient mice of LPS-treated donors were diabetic. Remarkably, in the same group, four of 14 mice were still not diabetic 25 weeks post-transfer. Similar experiments performed with males yielded comparable results (Fig. S7A). As recipient mice were not exposed to LPS, we conclude that LPS altered the lymphocyte composition in the protected donors.